With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
|Videos|November 29, 2017
Dr. Sabbatini on Novel Approaches With IP Therapy For Ovarian Cancer
Author(s)Paul Sabbatini, MD
Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.
Advertisement
Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.
Dose-dense therapy or every-3-week therapy allows for many additional combinations in the primary setting, explains Sabbatini. Adding PARP inhibitors, maintenance therapy, anti-vascular agents, or other novel compounds are currently being investigated.
According to Sabbatini, it would be difficult to incorporate those into an IP with cisplatin.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5